Drugs Containing Excipient (Inactive Ingredient) CALCIUM ACETATE

Generic drugs containing CALCIUM ACETATE excipient

Company	Ingredient	NDC	Excipient
Liberty Pharmaceuticals Inc	atorvastatin calcium	0440-7128	CALCIUM ACETATE
NCS HealthCare of KY LLC dba Vangard Labs	atorvastatin calcium	0615-8006	CALCIUM ACETATE
NCS HealthCare of KY LLC dba Vangard Labs	atorvastatin calcium	0615-8007	CALCIUM ACETATE
NCS HealthCare of KY LLC dba Vangard Labs	atorvastatin calcium	0615-8008	CALCIUM ACETATE

Calcium Acetate Pharmaceutical Excipient Market Dynamics, Patent Status, and Financial Trajectory

Last updated: August 16, 2026

Calcium acetate is a low-cost, mature pharmaceutical chemical with limited standalone financial disclosure. Its principal pharmaceutical role is as an active phosphate binder for patients with end-stage renal disease, not as a high-value excipient. Market demand is stable but structurally constrained by generic competition, low unit pricing, calcium-loading concerns, and substitution by non-calcium phosphate binders such as sevelamer, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide.

The commercial opportunity is concentrated in regulated, pharmaceutical-grade supply, manufacturing reliability, and contract supply rather than breakthrough formulation patents. Publicly reported company revenue for calcium acetate is generally unavailable because manufacturers aggregate the product within generic portfolios or do not report it separately.

What is calcium acetate used for in pharmaceuticals?

Calcium acetate is primarily used as an oral phosphate binder. It binds dietary phosphate in the gastrointestinal tract and reduces serum phosphate in patients with kidney failure on dialysis. Approved products include capsules, tablets, and oral solutions or suspensions depending on jurisdiction and product sponsor.

The compound is often described commercially as calcium acetate, calcium acetate anhydrous, or calcium acetate monohydrate. Its CAS Registry Number is 62-54-4. Pharmaceutical-grade material must meet applicable identity, assay, impurity, microbial, and elemental impurity requirements.

In approved calcium acetate medicines, calcium acetate is the active pharmaceutical ingredient, or API. It should not be treated as a conventional inactive excipient in those products. Its use as a formulation aid or processing material may exist in specialized products, but that application is not the main driver of pharmaceutical demand.

What dosage forms contain calcium acetate?

Common dosage forms include:

• Hard gelatin capsules
• Immediate-release tablets
• Chewable tablets
• Oral solutions or suspensions
• Combination phosphate-binding products in selected markets

A frequently marketed strength is 667 mg calcium acetate per capsule or tablet. That amount provides approximately 169 mg of elemental calcium, according to U.S. product labeling.[1]

Calcium acetate is also used outside finished pharmaceuticals in food, chemical, and industrial applications. Those markets can affect manufacturing economics, but they do not carry the same regulatory premium as drug-grade calcium acetate.

How large is the calcium acetate pharmaceutical market?

No authoritative public source reports a separately audited global market size for pharmaceutical-grade calcium acetate. Market-research estimates that combine calcium salts, phosphate binders, or pharmaceutical excipients should not be treated as calcium acetate revenue.

The addressable pharmaceutical market has four commercial layers:

Market layer	Demand profile	Pricing profile	Strategic value
Pharmaceutical-grade calcium acetate API	Stable, recurring	Low to moderate	Quality and supply reliability
Finished generic phosphate binders	Mature and competitive	Low	Distribution and manufacturing scale
Branded or specialty formulations	Limited	Higher	Formulation and channel access
Nonpharmaceutical calcium acetate	Broader industrial demand	Commodity-sensitive	Plant utilization and cost absorption

Demand is linked to the dialysis population and treatment practices. The United States had more than 800,000 people living with end-stage kidney disease in recent U.S. reporting periods, with dialysis representing the dominant treatment modality.[2] That creates a durable patient base, but not a high-growth market for calcium acetate because phosphate-binder treatment is divided among multiple drug classes.

Calcium acetate volume is therefore more likely to grow in line with dialysis prevalence and access to treatment than with pharmaceutical price expansion.

What is driving calcium acetate market demand?

Dialysis population growth

Growth in chronic kidney disease, diabetes, hypertension, and aging populations supports long-term demand for phosphate binders. Expansion of dialysis capacity in emerging markets can increase unit volume, particularly where low-cost generic therapies are favored.

Low cost of therapy

Calcium acetate is generally less expensive than newer phosphate binders. In cost-sensitive health systems, the product remains commercially relevant even when clinicians prefer calcium-free alternatives for selected patients.

Generic availability

The active ingredient has been used for decades, and multiple generic suppliers can manufacture the product. Generic availability reduces supply concentration and limits price increases.

Institutional purchasing

Dialysis providers, hospital systems, government programs, and specialty pharmacies can purchase phosphate binders through formularies and tenders. These channels favor dependable supply, regulatory compliance, and low landed cost.

What factors are limiting calcium acetate growth?

The main limitation is therapeutic substitution. Clinical practice has increasingly focused on controlling calcium exposure in dialysis patients, especially when patients have hypercalcemia, vascular calcification, adynamic bone disease, or other mineral-bone complications.

Guidelines from Kidney Disease: Improving Global Outcomes recommend restricting calcium-based phosphate binders in certain patients and circumstances, particularly where hypercalcemia or vascular calcification is present.[3] This does not eliminate calcium acetate use, but it reduces its role in patients who are candidates for non-calcium alternatives.

Competitors include:

Product	Active ingredient	Commercial positioning
Calcium acetate	Calcium acetate	Low-cost calcium-based binder
Renvela, generics	Sevelamer carbonate or hydrochloride	Calcium-free polymer binder
Fosrenol	Lanthanum carbonate	Calcium-free metal-based binder
Auryxia	Ferric citrate	Iron-based binder
Velphoro	Sucroferric oxyhydroxide	Iron-based, lower-pill-burden positioning

Newer products generally have higher prices and stronger branded commercial support. Calcium acetate competes on cost and familiarity rather than differentiated clinical or formulation technology.

When does calcium acetate lose market exclusivity?

Calcium acetate has no meaningful remaining new-chemical-entity exclusivity in the United States. The active ingredient is a mature compound, and generic products are available.

The relevant commercial barriers are regulatory and operational rather than exclusivity-based:

• FDA approval of the finished dosage form
• Drug Master File or equivalent API support
• cGMP manufacturing
• Validated impurity and elemental impurity controls
• Stability data
• Reliable supply of pharmaceutical-grade raw materials
• Customer qualification and audit history

For mature generic products, a supplier can face significant market-entry costs even when the underlying compound is unpatented. These costs do not create durable market exclusivity, but they can delay entry or limit the number of qualified suppliers.

What patents protect calcium acetate products?

The basic calcium acetate molecule is not protected by a current U.S. composition-of-matter patent. Any foundational patent protection would have expired long ago.

Potentially relevant rights can include:

• Product-specific formulation patents
• Controlled-release or taste-masking patents
• Combination-product patents
• Manufacturing-process patents
• Use patents directed to particular patient populations or dosing regimens
• Packaging or device rights for liquid or unit-dose products

These rights are distinct from protection for the calcium acetate molecule itself. A generic immediate-release calcium acetate product normally faces a mature compound with limited patent risk.

What is the Orange Book status of calcium acetate?

FDA Orange Book status must be evaluated by specific reference-listed drug and dosage form. Calcium acetate products may appear as approved prescription products, while individual listings can have discontinued, withdrawn, or generic status depending on sponsor and product.

The Orange Book does not create market exclusivity for an excipient or API. It identifies approved drug products and, where applicable, listed patents and regulatory exclusivities. For calcium acetate, the practical assessment is that Paragraph IV risk is generally low for the active ingredient and higher only where a particular listed formulation or method-of-use patent remains relevant.[4]

Are there Paragraph IV challenges to calcium acetate?

Paragraph IV litigation is not the principal market risk for ordinary calcium acetate products. The product class is mature, and generic entry has already occurred in major markets.

A Paragraph IV filing could arise if a sponsor lists a formulation, combination, or method-of-use patent for a specific calcium acetate product. The economic value of such litigation would depend on:

1. Whether the patent is listed for the targeted reference product.
2. Whether the generic product would infringe the asserted claims.
3. Whether the patent covers the active ingredient, formulation, dosing method, or only a narrow presentation.
4. Whether the reference product has sufficient remaining commercial sales to justify litigation.

For a low-price generic product, litigation economics often favor a non-infringing design, a Paragraph III filing, or commercial entry after patent expiry rather than prolonged litigation.

What formulation patents could protect calcium acetate?

Formulation protection is more plausible than molecule protection. Relevant technical areas include:

Taste masking

Calcium salts can create a chalky or unpleasant oral experience. Coatings, granulation systems, flavoring, and particle engineering can support chewable or liquid presentations.

High-load tablets

Calcium acetate requires a substantial active mass to deliver the prescribed dose. Tablet hardness, friability, disintegration, and swallowability create formulation challenges.

Oral liquids and suspensions

Liquid products require control of sedimentation, redispersibility, pH, microbial stability, and dose uniformity. A novel suspension system could support patent claims, although commercial value depends on product uptake.

Combination products

A product combining calcium acetate with another phosphate binder, mineral-bone agent, or adherence technology could have greater patent potential than calcium acetate alone. Such patents would protect the combination or dosage regimen, not the basic calcium acetate molecule.

Manufacturing methods

Process claims may cover crystallization, particle-size control, impurity reduction, drying, or continuous manufacturing. Process patents are commercially relevant only if the claimed process is difficult to design around and the resulting material is needed for a regulated product.

How strong is the calcium acetate patent estate?

The core patent estate is weak from a molecule perspective and moderate-to-low from a standard immediate-release product perspective.

Patent category	Current strength	Commercial assessment
Composition of matter	Very low	Mature compound
Standard immediate-release capsule	Low	Generic substitution is established
High-load tablet formulation	Low to moderate	Potentially useful if claims are narrow and enforceable
Liquid or suspension formulation	Moderate in specific products	Technical differentiation possible
Combination products	Moderate	Depends on clinical and formulation claims
Manufacturing process	Variable	Relevant to supplier qualification and cost
Method of use	Low to moderate	Narrow patient or dosing claims may remain

Patent strength should be assessed at the product level. A supplier with no product patent can still maintain a defensible position through regulatory files, customer qualification, validated processes, and supply consistency.

Which companies compete in calcium acetate?

The competitive landscape includes generic pharmaceutical manufacturers, API producers, contract development and manufacturing organizations, and regional suppliers. The market is fragmented and typically includes companies with broad generic portfolios rather than calcium acetate specialists.

Major branded phosphate-binder companies compete indirectly with calcium acetate:

• Sanofi and legacy Genzyme products associated with Renvela
• Keryx Biopharmaceuticals, now part of Akebia Therapeutics, associated with Auryxia
• Vifor Pharma, now part of CSL, associated with Velphoro
• Shire and later Takeda-associated products involving Fosrenol

These products have higher commercial value but do not indicate that the companies control calcium acetate supply. Generic calcium acetate is usually sourced through approved manufacturers and distributors.

What is the financial trajectory for calcium acetate?

The financial trajectory is best described as stable volume, declining or flat real pricing, and limited standalone margin expansion.

Revenue profile

Public companies generally do not disclose calcium acetate revenue separately. Reported revenue is usually aggregated into generic pharmaceuticals, renal products, hospital products, or contract manufacturing.

The product’s financial contribution depends on:

• API yield and raw-material costs
• Plant utilization
• Customer concentration
• Regulatory status in each market
• Packaging and dosage-form complexity
• Tender pricing
• Freight and energy costs
• Rejection, recall, and compliance risk

Margin profile

API margins are likely to be lower than those for patented or technically complex APIs. Finished-dose margins can improve through automated high-volume production, but price competition remains intense.

A supplier can improve economics through:

• Multi-market regulatory approvals
• Integrated API and finished-dose manufacturing
• High-volume contracts with dialysis networks
• Low-cost granulation and tableting
• Dual-use manufacturing assets
• Reliable inventory and short lead times

Scenario outlook

Scenario	Market effect	Financial consequence
Base case	Dialysis growth offsets gradual substitution	Stable volume; limited price growth
Downside case	Faster adoption of calcium-free binders and aggressive tenders	Lower volume and compressed margins
Upside case	Greater dialysis access in emerging markets	Volume growth, but pricing remains constrained
Supply disruption case	API or cGMP failure at a qualified supplier	Temporary price increases and customer switching

The strongest financial risk is not patent expiry. It is substitution and commoditization.

What regulatory status applies to calcium acetate?

In the United States, calcium acetate phosphate binders are regulated as prescription drugs. Product sponsors must establish quality, safety, efficacy, manufacturing compliance, and labeling through the applicable FDA pathway.

An API supplier may support multiple finished products through a Drug Master File or customer-specific regulatory submissions. The regulatory value of an API supplier increases when its manufacturing site is approved or referenced across several markets.

For excipient use, the regulatory pathway differs. An excipient does not generally receive the same product-specific approval as an API. Its acceptability depends on intended use, concentration, route of administration, compendial status, prior use, supplier documentation, and the finished product sponsor’s regulatory justification.

What geographic markets offer the greatest opportunity?

The United States remains commercially important because of its large dialysis population, established reimbursement, and mature generic market. Europe is also significant, but national reimbursement and tender systems affect pricing.

Emerging markets can offer stronger unit-growth potential because dialysis access is expanding. Commercial success depends on local registration, price controls, distribution, and the ability to meet pharmaceutical-grade standards at low cost.

Geographic diversification reduces reliance on one tender or reimbursement system. It also raises compliance costs because specifications, filings, pharmacopoeial references, and change-control expectations differ across jurisdictions.

What generic launch risks exist for calcium acetate?

Generic launch risk is usually moderate operationally and low legally. The main risks are:

• Failure to demonstrate bioequivalence or pharmaceutical equivalence
• Finished-product impurities or inconsistent assay
• Difficulty meeting dissolution or content-uniformity specifications
• API supplier qualification delays
• Labeling and dosage-strength differences
• Reimbursement exclusion
• Incumbent price retaliation
• Limited pharmacy or dialysis-network access

Because the compound is mature, regulatory execution and commercial contracting matter more than patent litigation.

Key Takeaways

• Calcium acetate is primarily a pharmaceutical API and phosphate binder, not a high-value conventional excipient.
• The market has durable demand from dialysis but limited pricing power.
• Public companies generally do not report calcium acetate revenue separately.
• The molecule has no meaningful remaining composition-of-matter exclusivity.
• Ordinary calcium acetate generics face limited Paragraph IV and patent litigation risk.
• Formulation, combination, liquid, taste-masking, and manufacturing-process patents can create narrower protection.
• Sevelamer, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide constrain long-term growth.
• Financial performance depends on volume, manufacturing efficiency, regulatory qualification, and tender access.
• The base-case outlook is stable volume with flat-to-compressed margins.
• Emerging-market dialysis expansion provides the clearest volume-growth opportunity.

FAQs about calcium acetate pharmaceutical markets

Is calcium acetate an API or an excipient?

In phosphate-binder medicines, calcium acetate is the API because it produces the therapeutic effect of binding dietary phosphate. Its use as an excipient is secondary and not the main pharmaceutical market driver.

Does calcium acetate have a high-value specialty-chemical market?

No. Pharmaceutical-grade calcium acetate can command a quality premium, but the compound is mature and relatively simple. Its value is based on compliance, purity, supply reliability, and customer qualification rather than molecular novelty.

Can a calcium acetate supplier obtain patent protection today?

A supplier is unlikely to obtain broad composition-of-matter protection for calcium acetate. Patent opportunities may exist for narrow formulations, combinations, delivery systems, or manufacturing processes.

Are calcium acetate products exposed to biosimilar competition?

No. Calcium acetate is a small-molecule compound, not a biologic. Competition comes from generic drugs and therapeutic substitutes, not biosimilars.

What is the main investment risk in calcium acetate?

The main risk is margin erosion from generic competition and substitution by calcium-free phosphate binders. Regulatory compliance failures and loss of a qualified API source can create short-term disruption but do not usually produce durable market power.

References

1. U.S. Food and Drug Administration. (2023). Calcium acetate capsule prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. United States Renal Data System. (2023). 2023 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases. https://usrds-adr.niddk.nih.gov/

3. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book